Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Drug: FCR
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 40
- Registration Number
- NCT00801060
- Locations
- 🇺🇸
University of Florida/Pulmonary, Critical Care & Sleep Medicine, Gainesville, Florida, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸Vanderbilt University Medical Center-IPF Program, Nashville, Tennessee, United States
Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
- Conditions
- Crohn's Disease
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Registration Number
- NCT00801125
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: BG9418 (interferon beta 1-a)
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Biogen
- Target Recruit Count
- 3
- Registration Number
- NCT00784836
- Locations
- 🇺🇸
MS Center at Texas Neurology, Dallas, Texas, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: Placebo (sterile normal saline)
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 53
- Registration Number
- NCT00771329
- Locations
- 🇷🇺
Research Centre, Yaroslavl, Russian Federation
🇺🇸Research Site, Oklahoma City, Oklahoma, United States
A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Biogen
- Registration Number
- NCT00771043
Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Biogen
- Target Recruit Count
- 37
- Registration Number
- NCT00746941
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency
- Conditions
- Renal InsufficiencyHeart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 34
- Registration Number
- NCT00745316
A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT00744679
- Locations
- 🇺🇸
Research Site, Latham, New York, United States
Administration of BIIB028 to Subjects With Solid Tumors
- Conditions
- Advanced Solid Tumors
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 43
- Registration Number
- NCT00725933
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency
- Conditions
- Renal InsufficiencyCongestive Heart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 420
- Registration Number
- NCT00709865